Belatacept: Is there BENEFIT for liver transplantation too?

S. J. Knechtle, A. B. Adams

Research output: Contribution to journalEditorialpeer-review

11 Scopus citations


The results of the multicenter belatacept liver transplant trial disappoint with respect to safety and efficacy, and new approaches will be required before this agent plays a role in liver transplant immunosuppression. See article by Klintmalm et al on page 1817.

Original languageEnglish (US)
Pages (from-to)1717-1718
Number of pages2
JournalAmerican Journal of Transplantation
Issue number8
StatePublished - Aug 2014
Externally publishedYes

Bibliographical note

Funding Information:
The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. SJK is a stockholder of Bristol Myers Squibb. ABA receives grant money from Bristol Myers Squibb.


Dive into the research topics of 'Belatacept: Is there BENEFIT for liver transplantation too?'. Together they form a unique fingerprint.

Cite this